Yale-METRO Metropolitan Emergency Trial netwoRK to advance patient Outcomes

The Yale-Metropolitan Emergency Trial network to advance patient Outcomes (Yale-METRO) is anchored by Yale New Haven Health System (YNHHS) as the Hub and 5 leading partner integrated health systems (1) Hartford Healthcare, (2) Rhode Island/Brown University Health System, (3) Mount Sinai Health System, (4) New York Presbyterian/Weill Cornell Medicine, and (5) Montefiore Health System. Yale-New Haven Hospital is the 7th largest hospital in the U.S. and in collaboration with YNHHS and the Spokes with their respective networks these geographically proximate institutions, cover a densely populated catchment area including more than 8 million people throughout Connecticut, Rhode Island, Southeast NY, Southern MA, and 4 boroughs of New York City, with 1,739,027 Emergency Department visits offering access to a large and diverse population of acutely ill adult and pediatric patients. Principal Investigators Dr. Gail D'Onofrio (Emergency Medicine) and Dr. Kevin Sheth (Neurology) bring a complementary set of leadership skills, high-level clinical trial experience, and an excellent organizational framework. Each have demonstrated expertise in leading and conducting multicenter trials, and a proven track record of high-quality ED and pre-hospital recruitment, and retention in studies, even during the COVID-19 Pandemic. They have collaborated and are actively engaged in multicenter trials with the Spoke institutions and investigators. These interactions include leveraging successful contributions currently in place for NIH networks such as NeuroNEXT and Stroke Net. They have access to a cadre of impressive multispecialty faculty, creating a highly collaborative environment focused on the emergency care related to presentations and diagnoses of interest including, neurological, cardiovascular, respiratory, hematology and trauma. Finally, they have created mechanisms to facilitate enrollment 24 hours, 7 days a week that are already in place. The proposal is strengthened by a: (1) Pool of talented investigators with nationally recognized researchers and MPIs with experience implementing multicenter trials (2) Large diverse patient population (3) Informaticist and analytic team bringing innovative technological strategies and processes for rapid uptake of Spokes, recruitment, data collection, monitoring and quality; (4) Robust track record of mentoring junior investigators and (5) Expertise in developing future proposals for SIREN research. Yale-METRO offers all the components for conducting high-quality research and unique opportunities to use innovative technology advances for disease detection, patient enrollment, data collection and high-quality assurances procedures. Thus, Yale-METRO offers unique opportunities to strengthen the SIREN Network, designing, testing, and discovering interventions and therapies improving patient outcomes.